(Q36922264)

17 August 2017

1 reference

title

Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer (English)

1 reference

17 August 2017

1 reference

Myxoma virus

1 reference

2

Grant McFadden

1 reference

17 August 2017

Marianne M Stanford

1

1 reference

PubMed ID

17727330

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

1415-1425

1 reference

17 August 2017

9

1 reference

Stem cell collection and gene transfer in Fanconi anemia

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Recent clinical progress in virus-based therapies for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Fighting cancer with oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Immunopathogenesis of poxvirus infections: forecasting the impending storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Varicella-zoster virus requires a functional PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Biochemical aspects of coronavirus replication and virus-host interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Oncolytic viruses: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Oncolytic virus therapy--foreword

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Oncolytic viral therapies - the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Getting oncolytic virus therapies off the ground

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Fighting cancer with vaccinia virus: teaching new tricks to an old dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Cell proliferative response to vaccinia virus is mediated by VGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Vaccinia as a vector for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Virology- and immunology-based gene therapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The potential role of fowlpox virus in rational vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Development of the PANVAC-VF vaccine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Myxoma virus in the European rabbit: interactions between the virus and its susceptible host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Immune responses to myxoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Immunomodulatory proteins of myxoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Everolimus: a review of its use in renal and cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Secreted immunomodulatory viral proteins as novel biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

21 January 2018

Poxvirus cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1415

10.1517/14712598.7.9.1415

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17727330